Higher body mass index (BMI) is independently associated with improved survival of patients with metastatic and castration-resistant prostate cancer (PCa), according to study findings presented at the 2017 Genitourinary Cancers Symposium in Orlando, Florida.
In a study of 79 patients with metastatic or castration-resistant PCa, Zachary A. Glaser and colleagues at Vanderbilt University Medical Center in Nashville, Tennessee, found that each 1-unit increment in BMI was associated with a significant 16% lower risk of death in multivariate analysis.
The study cohort had a mean age of 64 years, and 69% of patients were Caucasian. The median BMI was 28.5 kg/m2. Of the 79 patients, 25 (31.6%) were obese (BMI of 30 kg/m2 or higher) and 18 (22.7%) had diabetes mellitus.
The estimated 5-year overall survival rate was significantly lower among patients with diabetes mellitus than without (77.1% vs. 92.7%). The estimated 5-year OS rate was 93.9% for obese patients compared with 84.1% for non-obese patients, a non-significant difference.
According to senior investigator Kelvin Moses, MD, PhD, FACS, these findings suggest that increased reserve may be protective in patients with advanced prostate cancer.
See more coverage from the Genitourinary Cancers Symposium.
1. Glaser Z, Avulova S, Stocks B, et al. The association of BMI and DM with survival among patients with metastatic and/or castration-resistant prostate cancer. Data presented in poster format at the 2017 Genitourinary Cancers Symposium in Orlando, Florida. Poster Session A Board #H9. Abstract 207.